CLINICAL MICROSCOPY PROGRESS EXAM PART 2

Yves Laure Pimentel · 70問 · 2年前

通報

問題一覧

How many nephrons are found in the average kidney? * 1/1 13,000 130,000 1.3 million 13 million

1.3 million

The fluid leaving the glomerulus has a specific gravity of: * 1/1 1.005 1.010 1.015 1.020

1.010

The primary chemical constituents of normal urine are: * 1/1 Protein, sodium, and water Urea, water, and protein Urea, chloride, and water Urea, bilirubin, and glucose

Urea, chloride, and water

A person exhibiting oliguria would have a daily urine volume of: * 1/1 200 to 400 mL 600 to 1,000 mL 1,000 to 1,500 mL Over 1,500 mL

200 to 400 mL

For best preservation of urinary sediments, the preservatives of choice are: * 1/1 Boric acid and thymol Toluene and freezing Formalin and sodium fluoride Chloroform and refrigeration

Boric acid and thymol

What type of urine specimen should be collected from a patient who complains of painful urination and the physician has ordered a routine urinalysis and urine culture? * 0/1 Random First morning Fasting Midstream clean-catch

Midstream clean-catch

The concentration of a normal urine specimen can be estimated by which of the following? * 1/1 Color Clarity Foam Odor

Color

In what circumstance might a sediment be slightly warmed prior to microscopic examination? * 0/1 To hemolyze RBCs To dissolve amorphous urates To increase the specific gravity To correct for temperature in determining the specific gravity

To dissolve amorphous urates

Refractive index compares: * 0/1 Light velocity in solutions with light velocity in solids Light velocity in air with light velocity in solutions Light scattering by air with light scattering by solutions Light scattering by particles in solution

Light velocity in air with light velocity in solutions

Leaving a reagent strip in the specimen for too long will: * 0/1 Cause runover between reagent pads Alter the color of the specimen Cause reagents to leach from the pads Not affect the chemical reactions

Cause reagents to leach from the pads

Failure to mix a specimen prior to inserting the reagent strip will primarily affect the: * 1/1 Glucose reading Blood reading Nitrite reading pH reading

Blood reading

Testing a refrigerated specimen that has not warmed to room temperature will adversely affect: * 0/1 Enzymatic reactions Dye-binding reactions The sodium nitroprusside reaction Diazo reactions

Enzymatic reactions

Testing for microalbuminuria is valuable for monitoring patients with: * 1/1 Hypertension Diabetes mellitus Cardiovascular disease risk All of the above

All of the above

All of the following are true for the Micral-Test for microalbumin except: * 0/1 It is run on first morning specimens It contains an antibody-enzyme conjugate Two blue bands are formed on the strip Unbound antibody attaches to immobilized albumin

Two blue bands are formed on the strip

The purpose of performing an albumin:creatinine ratio is to: * 0/1 Estimate the glomerular filtration rate Correct for hydration in random specimens Avoid interference for alkaline urines Correct for abnormally colored urines

Correct for hydration in random specimens

An elevated urine bilirubin with a normal urobilinogen is indicative of: * 1/1 Cirrhosis of the liver Hemolytic disease Hepatitis Biliary obstruction

Biliary obstruction

The principle of the reagent strip test for specific gravity uses the dissociation constant of a/an: * 1/1 Diazonium salt Indicator dye Polyelectrolyte Enzyme substrate

Polyelectrolyte

Mononuclear leukocytes are sometimes mistaken for: * 0/1 Yeast cells Squamous epithelial cells Pollen grains Renal tubular cells

Renal tubular cells

Transitional epithelial cells are sloughed from the: * 0/1 Collecting duct Vagina Bladder Proximal convoluted tubule

Bladder

Forms of transitional epithelial cells include all of the following except: * 0/1 Spherical Caudate Convoluted Polyhedral

Convoluted

The shape of the RTE cell associated with renal tubular epithelial casts is primarily: * 1/1 Elongated Cuboidal Round Columnar

Round

All of the following contribute to the formation of urinary crystals except: * 0/1 Protein concentration pH Solute concentration Temperature

Protein concentration

Who are the laboratory’s “customers” in CQI? * 1/1 Physicians Patients’ family members Patients All of the above

All of the above

What is the primary goal of TQM? * 0/1 Increased laboratory productivity Improved patient outcomes Reliability of test results Precise test results

Improved patient outcomes

CSF can be differentiated from plasma by the presence of: * 1/1 Albumin Globulin Prealbumin Tau transferrin

Tau transferrin

Maturation of spermatozoa takes place in the: * 1/1 Sertoli cells Seminiferous tubules Epididymis Seminal vesicles

Epididymis

Measurement of alpha-glucosidase is performed to detect a disorder of the: * 1/1 Seminiferous tubules Epididymis Prostate gland Bulbourethral glands

Epididymis

Enzymes for the coagulation and liquefaction of semen are produced by the: * 1/1 Seminal vesicles Bulbourethral glands Ductus deferens Prostate gland

Prostate gland

An increase in the amount of serous fluid is called a/an * 1/1 Exudate Transudate Effusion Malignancy

Effusion

Which test for FLM is LEAST affected by contamination with hemoglobin and meconium? * 0/1 Amniostat-FLM Foam Stability Lamellar Bodies Count TDx-FLM II

Amniostat-FLM

Which of the following tests is NOT performed to detect osmotic diarrhea? * 0/1 Clinitest Fecal fats Fecal neutrophils Muscle fibers

Fecal neutrophils

A black tarry stool is indicative of: * 1/1 Upper GI bleeding Lower GI bleeding Excess fat Excess carbohydrates

Upper GI bleeding

Secretory diarrhea is caused by: * 0/1 Antibiotic administration Lactose intolerance Celiac sprue Vibrio cholerae

Vibrio cholerae

The fecal osmotic gap is elevated in which disorder? * 1/1 Dumping syndrome Osmotic diarrhea Secretory diarrhea Steatorrhea

Osmotic diarrhea

The term “occult” blood describes blood that: * 1/1 Is produced in the lower GI tract Is produced in the upper GI tract Is not visibly apparent in the stool specimen Produces a black, tarry stool

Is not visibly apparent in the stool specimen

other names parasitology

other names parasitology

70問 • 2年前

Yves Laure Pimentel · 111問 · 2年前

PARASITOLOGY

PARASITOLOGY

111問 • 2年前

Yves Laure Pimentel · 64問 · 2年前

HTMLBE

HTMLBE

64問 • 2年前

Yves Laure Pimentel · 61問 · 2年前

CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

61問 • 2年前

Yves Laure Pimentel · 69問 · 2年前

HISTOPATHOLOGY

HISTOPATHOLOGY

69問 • 2年前

CC-2 SPECTROPHOTOMETRY

CC-2 SPECTROPHOTOMETRY

Yves Laure Pimentel · 41問 · 2年前

CC-3 ELECTROPHORESIS

CC-3 ELECTROPHORESIS

41問 • 2年前

Yves Laure Pimentel · 87問 · 2年前

AUBF LAB SAFETY

AUBF LAB SAFETY

87問 • 2年前

CSF 1

CSF 1

Yves Laure Pimentel · 82問 · 2年前

CSF 2

CSF 2

82問 • 2年前

SEMEN 1

SEMEN 1

Yves Laure Pimentel · 7問 · 2年前

SEMEN 2

SEMEN 2

7問 • 2年前

SYNOVIAL FLUID 1

SYNOVIAL FLUID 1

Yves Laure Pimentel · 6問 · 2年前

SYNOVIAL FLUID 2

SYNOVIAL FLUID 2

6問 • 2年前

Yves Laure Pimentel · 25問 · 2年前

SEROUS FLUID

SEROUS FLUID

25問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

PLEURAL FLUID

PLEURAL FLUID

44問 • 2年前

Yves Laure Pimentel · 18問 · 2年前

PERICARDIAL FLUID

PERICARDIAL FLUID

18問 • 2年前

Yves Laure Pimentel · 30問 · 2年前

PERITONEAL FLUID/ ASCITIC FLUID

PERITONEAL FLUID/ ASCITIC FLUID

30問 • 2年前

Yves Laure Pimentel · 92問 · 2年前

AMNIOTIC FLUID

AMNIOTIC FLUID

92問 • 2年前

Yves Laure Pimentel · 80問 · 2年前

FECALYSIS

FECALYSIS

80問 • 2年前

Yves Laure Pimentel · 89問 · 2年前

OTHER BODY FLUIDS

OTHER BODY FLUIDS

89問 • 2年前

Yves Laure Pimentel · 86問 · 2年前

MTLBE- SUHO NOTES

MTLBE- SUHO NOTES

86問 • 2年前

Yves Laure Pimentel · 35問 · 2年前

MTLBE..

MTLBE..

35問 • 2年前

Yves Laure Pimentel · 19問 · 1年前

CC- CHROMATOGRAPHY

CC- CHROMATOGRAPHY

19問 • 1年前

Yves Laure Pimentel · 14問 · 1年前

CC-OSMOMETRY

CC-OSMOMETRY

14問 • 1年前

Yves Laure Pimentel · 43問 · 1年前

CC-ELECTROCHEMISTRY TECHNIQUES

CC-ELECTROCHEMISTRY TECHNIQUES

43問 • 1年前

Yves Laure Pimentel · 49問 · 2年前

CC- CARBOHYDRATES

CC- CARBOHYDRATES

49問 • 2年前

Yves Laure Pimentel · 97問 · 2年前

CC- DIABETES MELLITUS

CC- DIABETES MELLITUS

97問 • 2年前

Yves Laure Pimentel · 57問 · 2年前

MAJOR LIPOPROTEINS

MAJOR LIPOPROTEINS

57問 • 2年前

Yves Laure Pimentel · 63問 · 2年前

MINOR LIPOPROTEINS

MINOR LIPOPROTEINS

63問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

PROTEINS

PROTEINS

37問 • 2年前

Yves Laure Pimentel · 91問 · 2年前

PLASMA PROTEINS 1

PLASMA PROTEINS 1

91問 • 2年前

Yves Laure Pimentel · 98問 · 2年前

PLASMA PROTEINS 2 (ALPHA 2 REGION)

PLASMA PROTEINS 2 (ALPHA 2 REGION)

98問 • 2年前

Yves Laure Pimentel · 61問 · 2年前

MISCELLANEOUS PROTEINS

MISCELLANEOUS PROTEINS

61問 • 2年前

Liver Function Test 1

Liver Function Test 1

Yves Laure Pimentel · 96問 · 2年前

Liver Function Test 2

Liver Function Test 2

96問 • 2年前

Yves Laure Pimentel · 33問 · 2年前

TUMOR MARKERS

TUMOR MARKERS

33問 • 2年前

Yves Laure Pimentel · 41問 · 2年前

KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

41問 • 2年前

Yves Laure Pimentel · 17問 · 2年前

GLYCOGEN STORAGE DISEASES

GLYCOGEN STORAGE DISEASES

17問 • 2年前

Yves Laure Pimentel · 14問 · 2年前

LIPID STORAGE DISEASES

LIPID STORAGE DISEASES

14問 • 2年前

Yves Laure Pimentel · 71問 · 2年前

PROTEINS

PROTEINS

71問 • 2年前

Yves Laure Pimentel · 7問 · 2年前

QUICK FIRE- ELECTRODES

QUICK FIRE- ELECTRODES

7問 • 2年前

Yves Laure Pimentel · 10問 · 2年前

ELECTROLYTES

ELECTROLYTES

10問 • 2年前

Yves Laure Pimentel · 27問 · 2年前

DRUGS

DRUGS

27問 • 2年前

Yves Laure Pimentel · 12問 · 2年前

TOXIC AGENTS:

TOXIC AGENTS:

12問 • 2年前

HEMATOLOGY 1 (HEMATOPOIESIS 1)

HEMATOLOGY 1 (HEMATOPOIESIS 1)

Yves Laure Pimentel · 29問 · 2年前

HEMATOLOGY (HEMATOPOIESIS 2)

HEMATOLOGY (HEMATOPOIESIS 2)

29問 • 2年前

Yves Laure Pimentel · 25問 · 2年前

hema diseases

hema diseases

25問 • 2年前

Yves Laure Pimentel · 43問 · 2年前

AML

AML

43問 • 2年前

Yves Laure Pimentel · 71問 · 2年前

GLOBIN SYNTHESIS

GLOBIN SYNTHESIS

71問 • 2年前

Yves Laure Pimentel · 31問 · 2年前

HEMATOLOGY REFERENCE RANGES

HEMATOLOGY REFERENCE RANGES

31問 • 2年前

Yves Laure Pimentel · 34問 · 2年前

DISORDERS OF PRIMARY HEMOSTASIS

DISORDERS OF PRIMARY HEMOSTASIS

34問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

PLATELET DISORDERS

PLATELET DISORDERS

37問 • 2年前

CHARACTERISTICS OF CLOTTING FACTORS

CHARACTERISTICS OF CLOTTING FACTORS

Yves Laure Pimentel · 12問 · 2年前

4. CLASSIFICATION OF MACROPHAGE

4. CLASSIFICATION OF MACROPHAGE

12問 • 2年前

Yves Laure Pimentel · 39問 · 2年前

3. NATURAL OR INNATE IMMUNITY

3. NATURAL OR INNATE IMMUNITY

39問 • 2年前

Yves Laure Pimentel · 55問 · 2年前

5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

55問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

6. PHAGOCYTOSIS Chemotaxis

6. PHAGOCYTOSIS Chemotaxis

37問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

8. NATURE OF ANTIGEN

8. NATURE OF ANTIGEN

44問 • 2年前

Yves Laure Pimentel · 50問 · 2年前

9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

50問 • 2年前

Yves Laure Pimentel · 69問 · 2年前

1. HISTORY

1. HISTORY

69問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. TYPES OF IMMUNITY

2. TYPES OF IMMUNITY

38問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

7. PHAGOCYTOSIS Engulfment and Digestion

7. PHAGOCYTOSIS Engulfment and Digestion

21問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

8. PHAGOCYTOSIS EXOCYTOSIS

8. PHAGOCYTOSIS EXOCYTOSIS

15問 • 2年前

Yves Laure Pimentel · 32問 · 2年前

10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

32問 • 2年前

Yves Laure Pimentel · 30問 · 2年前

11. TRANSPLANTATION IMMUNOLOGY

11. TRANSPLANTATION IMMUNOLOGY

30問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. LYMPHOID ORGANS

2. LYMPHOID ORGANS

38問 • 2年前

Yves Laure Pimentel · 48問 · 2年前

3. CLUSTER OF DIFFERENTIATION

3. CLUSTER OF DIFFERENTIATION

48問 • 2年前

Yves Laure Pimentel · 35問 · 2年前

4. T-CELL DIFFERENTIATION

4. T-CELL DIFFERENTIATION

35問 • 2年前

Yves Laure Pimentel · 18問 · 2年前

5. T CELL IMMUNODEFICIENCIES

5. T CELL IMMUNODEFICIENCIES

18問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

44問 • 2年前

Yves Laure Pimentel · 23問 · 2年前

7. B CELL IMMUNODEFICIENCIES

7. B CELL IMMUNODEFICIENCIES

23問 • 2年前

Yves Laure Pimentel · 34問 · 2年前

8. COMBINED T CELL AND B CELL DEFICIENCIES

8. COMBINED T CELL AND B CELL DEFICIENCIES

34問 • 2年前

Yves Laure Pimentel · 12問 · 2年前

9. COMPARISON OF T AND B CELLS

9. COMPARISON OF T AND B CELLS

12問 • 2年前

Yves Laure Pimentel · 16問 · 2年前

10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

16問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

15問 • 2年前

Yves Laure Pimentel · 79問 · 2年前

12. ANTIBODY

12. ANTIBODY

79問 • 2年前

Yves Laure Pimentel · 97問 · 2年前

13. TYPES OF ANTIBODIES

13. TYPES OF ANTIBODIES

97問 • 2年前

Yves Laure Pimentel · 11問 · 2年前

14. MONOCLONAL ANTIBODIES

14. MONOCLONAL ANTIBODIES

11問 • 2年前

Yves Laure Pimentel · 23問 · 2年前

1. INTERLEUKINS

1. INTERLEUKINS

23問 • 2年前

Yves Laure Pimentel · 28問 · 2年前

2. INTERFERONS

2. INTERFERONS

28問 • 2年前

Yves Laure Pimentel · 8問 · 2年前

3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

8問 • 2年前

Yves Laure Pimentel · 19問 · 2年前

4. COMPLEMENT SYSTEM

4. COMPLEMENT SYSTEM

19問 • 2年前

Yves Laure Pimentel · 76問 · 2年前

15. COMPLEMENT SYSTEM

15. COMPLEMENT SYSTEM

76問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

16. SYSTEM CONTROLS/COMPLEMENT REGULATION

16. SYSTEM CONTROLS/COMPLEMENT REGULATION

21問 • 2年前

Yves Laure Pimentel · 29問 · 2年前

17. COMPLEMENT AND DISEASE STATES

17. COMPLEMENT AND DISEASE STATES

29問 • 2年前

Yves Laure Pimentel · 19問 · 2年前

18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

19問 • 2年前

Yves Laure Pimentel · 22問 · 2年前

19. CYTOKINES

19. CYTOKINES

22問 • 2年前

Yves Laure Pimentel · 24問 · 2年前

20. INTERLEUKINS

20. INTERLEUKINS

24問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

21. INTERFERONS, TNF, TGF, CHEMOKINE

21. INTERFERONS, TNF, TGF, CHEMOKINE

21問 • 2年前

Yves Laure Pimentel · 54問 · 2年前

1. SERO

1. SERO

54問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. PRECIPITATION

2. PRECIPITATION

38問 • 2年前

Yves Laure Pimentel · 17問 · 2年前

3. PASSIVE IMMUNODIFFUSION

3. PASSIVE IMMUNODIFFUSION

17問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

4. OUCHTERLONY

4. OUCHTERLONY

15問 • 2年前

Yves Laure Pimentel · 9問 · 2年前

5. ELECTROPHORETIC TECHNIQUE

5. ELECTROPHORETIC TECHNIQUE

9問 • 2年前

Yves Laure Pimentel · 11問 · 2年前

6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

11問 • 2年前

Yves Laure Pimentel · 29問 · 2年前

7. IMMUNOFIXATION ELECTROPHORESIS

7. IMMUNOFIXATION ELECTROPHORESIS

29問 • 2年前